Clinical trial
Type III Dysbetalipoproteinemia
NCT00214604 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00214604 |
|---|---|
| Title | Type III Dysbetalipoproteinemia |
| Official title | An 18-week, Randomized, Multicenter, Phase 3b, Double-blind, Crossover Study, Followed by an 18-week Open-Label Period to Evaluate the Efficacy & Safety of the Lipid-Regulating Agents, Rosuvastatin & Pravastatin in the Treatment of Subjects With Dysbetalipoproteinemia (Frederickson Type III… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hyperlipoproteinemia Type III |
| Intervention type | Drug |
| Interventions | Rosuvastatin, rosuvastatin, pravastatin |
| Enrollment | 30 |
| Start date | Feb 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 19, 2010 |
| Countries | Norway, South Africa |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: